Lucid Diagnostics (LUCD, Financial) has received a reiterated rating from Cantor Fitzgerald, as confirmed by analyst Ross Osborn. The stock's current rating remains "Overweight" and aligns with its previous status.
Cantor Fitzgerald has maintained its price target for Lucid Diagnostics (LUCD, Financial) at $2.00 USD. This consistent valuation suggests confidence in the company's market position and growth potential.
The analysis from May 15, 2025, indicates that the price target for Lucid Diagnostics (LUCD, Financial) has not changed, as it remains at $2.00 USD. The analysis did not indicate any percentage change in the price target.
Investors and market observers will watch to see if Lucid Diagnostics (LUCD, Financial) meets the reiterated expectations and achieves the set price target.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 6 analysts, the average target price for Lucid Diagnostics Inc (LUCD, Financial) is $3.75 with a high estimate of $7.50 and a low estimate of $2.00. The average target implies an upside of 198.80% from the current price of $1.26. More detailed estimate data can be found on the Lucid Diagnostics Inc (LUCD) Forecast page.
Based on the consensus recommendation from 6 brokerage firms, Lucid Diagnostics Inc's (LUCD, Financial) average brokerage recommendation is currently 1.8, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Lucid Diagnostics Inc (LUCD, Financial) in one year is $8.84, suggesting a upside of 604.38% from the current price of $1.255. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Lucid Diagnostics Inc (LUCD) Summary page.
